Critical Illness, Nonverbal Communication
Conditions
Keywords
Vidatalk, App, Augmentative and Alternative Communication, iPad, Android, Mechanical ventilation, Patient Communication, Critical Illness
Brief summary
This Phase II Small Business Technology Transfer Research (STTR) will deliver a comprehensive patient communication solution for communication-impaired patients in the intensive care unit that may help decrease days in delirium, decrease anxiety levels, and reduce sedation exposure which are proximal outcomes known to be associated with decreased mechanical ventilation days, shorter lengths of ICU and hospital stay, and lower healthcare cost. The primary goal of this Phase II STTR proposal is to further define user requirements and product specifications and develop a prototype of VidaTalk, a patient-centric, touch pad communication software, to provide mechanically ventilated (MV) patients an evidence-based solution for effectively communicating their needs to care providers and family. A secondary goal is to test the impact of the VidaTalk on clinical outcomes. This study will use mixed methods including observations and interaction with hospitalized patients as they use the VidaTalk tool, surveys and medical record data extraction, product evaluation and brief interview, satisfaction surveys with family members of ICU patients, and focus groups with Registered Nurses. Specific Aim 1. Develop a commercial prototype of VidaTalk that will include multilingual and customizable messages, compatibility with tablet devices, picture symbols, and integration with mobile communication devices. Specific Aim 2. Demonstrate usability with iterative user assessment testing in a clinical setting. Specific Aim 3. Test the clinical efficacy of VidaTalk via android application with MV patients by examining qualitative and quantitative endpoints in a clinical setting. Aim 3 hypothesis: MV patients using VidaTalk will demonstrate significant reductions in patient-reported communication difficulty and frustration, anxiety, sedation exposure, delirium/coma-free days, and improved patient and family satisfaction with ICU care compared to MV patients receiving attention-control (i.e., tablets with health education application). Specific Aim 4. Validation of electronic visual analogue scale, versus current standard paper scale. Specific Aim 5 a, b and c. Test the effect of the communication tablet (VidaTalk) on psychological symptoms in family caregivers.
Detailed description
Treatment-induced communication impairment is one of the most common and distressful symptoms to mechanically ventilated intensive care unit (ICU) patients and is associated with anxiety, panic, anger, frustration, sleeplessness, and distress.This Phase II Small Business Technology Transfer Research (STTR) will deliver a comprehensive solution that may help decrease days in delirium, decrease anxiety levels, and reduce sedation exposure which are proximal outcomes known to be associated with decreased mechanical ventilation days, shorter lengths of ICU and hospital stay, and lower healthcare cost. The primary goal of this Phase II STTR proposal is to further define user requirements and product specifications and develop a prototype of VidaTalk (previously TouchTalk), a patient-centric, touch pad communication software, to provide mechanically ventilated (MV) patients an evidence-based solution for effectively communicating their needs to care providers and family. A secondary goal is to test the impact of the VidaTalk on clinical outcomes (e.g., patient-reported communication difficulty and frustration, anxiety, sedation exposure, delirium/coma-free days, and improved patient and family satisfaction with ICU care). This study will use mixed methods including observations and interaction with hospitalized patients as they use the VidaTalk communication tool, surveys and medical record data extraction, product evaluation and brief interview, satisfaction survey with family members of ICU patients and focus groups with Registered Nurses. Our Phase I STTR successfully delivered a beta prototype that met technical feasibility criteria; however, additional requirements emerged as a common theme from user testing and market analysis. The current study will meet the identified needs for VidaTalk to operate on android devices, be customizable to patients' unique message needs, use pictures symbols for communication, and be able to route patient requests to providers who are not present at the bedside. Specific Aim 1 (Preliminary to Clinical Trial). Develop a commercial prototype of VidaTalk that will include multilingual and customizable messages, compatibility with tablet devices, picture symbols, and integration with mobile communication devices. Specific Aim 2 (Preliminary to Clinical Trial). Demonstrate usability with iterative user assessment testing in a clinical setting. Specific Aim 3. Test the clinical efficacy of VidaTalk via android application with MV patients by examining qualitative and quantitative endpoints in a clinical setting. Aim 3 hypothesis: MV patients using VidaTalk will demonstrate notable reductions in patient-reported frustration and communication difficulty, anxiety, sedation exposure, delirium/coma-free days, and improved patient and family satisfaction with ICU care compared to MV patients receiving attention-control. Specific Aim 4. Validation of electronic visual analogue scale, versus current standard paper scale. Specific Aim 5. Test the effect of the communication tablet (VidaTalk) on psychological symptoms in family caregivers.
Interventions
Observation of task completion will be made while patients complete a series of messages using the VidaTalk app: * Tell me you are tired * Tell me you are having pain * Rate this pain * Tell me there is pain in your back * Tell me your pain is sharp * Ask to see the doctor * Write your favorite color by drawing with your finger * Type How are you? Patients will also complete a 1-item difficulty rating and a 3-item After-Scenario Questionnaire (ASQ) after each task. Patients will also be asked to (a) comment on the customization of the app and make suggestions; (b) rate the extent to which they would use the device if they were an ICU patient and unable to speak. Group 1 only: Patients will be asked about their preferences for customizing the VidaTalk app.
Usability testing prior to clinical trial. The company will have performed further iterative design assessments and engineered a Vidatalk tablet application prototype for a field-test for functionality (human-device interaction factors, feasibility, and usability) and acceptability. Data will be collected by a trained data collector as in Aim 1 with the addition of Ease of Communication and Frustration ratings before and after the testing sequence. To reduce burden, patients in this group will complete the 3-item ASQ one time after all tasks are completed. They will also complete a 13-item System Usability Scale (SUS).
Patients in the intervention group will receive a protocolized instruction in the use of the VidaTalk application and mounting of the device including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.
Patents randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk app, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.
Sponsors
Study design
Eligibility
Inclusion criteria
Aim 1: Inclusion Criteria: 1. ≥18 years old 2. Able to communicate in English 3. Awake alert, responding appropriately to commands. 4. Normal (aided or unaided) hearing and vision 5. Able to control head, arm and hand movements 6. Physiologically stable and in no acute distress (per nurse report)
Exclusion criteria
1. Pre-existing communication impairments 2. Diagnosis of severe dementia or brain injury 3. CAM-ICU positive for delirium 4. unresponsiveness or inattention Aim 2: Inclusion Criteria: 1. ≥18 years old 2. Able to communicate in English 3. Awake alert, responding appropriately to commands. 4. Normal (aided or unaided) hearing and vision 5. Able to control head, arm and hand movements 6. Physiologically stable and in no acute distress (per nurse report) 7. Intubated via oral endotracheal or tracheal tube without speaking valve, receiving mechanical ventilation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Daily Patient-reported Communication Difficulty Rating Using Single Item 0-4 Rating Scale | Daily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICU | Aim 3 - Mean item score of daily by patient self report using a single item Likert-type scale from the Ease of Communication Scale (ECS) where scores range from 0 not hard at all to 4 extremely hard |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean Patient Frustration With Communication | Daily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICU | Aim 3 - This will be the calculated mean of the daily Communication Frustration scale - a single item scale reported by the patient, ranging from 0 not frustrating to 4 extremely frustrating |
| Mean Daily Sedation Exposure | Daily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICU daily in ICU | Used in Aim 3 only. Calculation of benzodiazepine and morphine equivalents (for opiates) using hospital conversion charts (pharmacy conversion chart). All benzo IV doses were converted to Lorazepam IV doses. All opioid IV doses were converted to morphine IV doses. All benzo oral doses were converted to Lorazepam oral doses. All opioid oral doses were converted to morphine oral doses. Oral doses were converted to IV equivalents. Summed doses of Lorazepam IV and morphine IV were calculated for each study day for each patient. Doses were converted to milligrams per kilogram based on the patient's body weight. Higher numbers indicate greater sedation and/or opiate exposure. |
| Ease of Communication at Extubation /ICU Discharge | measured at Extubation /ICU Discharge | Ease of Communication Scale -10-item likert scale total score ranging from 0-40. Each item is 0-4 likert scale, total score is sum of all items with higher scores indicating greater communication difficulty. |
| Percentage of Patients Scoring in the Calm Range During Study Days on Richmond Agitation Sedation Score | Daily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICU | The Richmond Agitation Sedation Scale, a 10-level observational rating of agitation-sedation motor activity ranging from +4 'combative' to -5 unresponsive, with 0 as calm. Since this is a categorical measure, we compared proportion of patients with RASS in -1 to +1 (calm) range during study days. |
| Delirium/Coma -Free Days | Daily, from enrollment to 28 days post-enrollment | Aim 3 -Delirium/coma-free days is defined as the number of days alive and free of delirium and coma during the 28-day study period. Delirium will be coded as present when a patient displays both features 1 and 2, and either 3 or 4 of the CAM-ICU (Confusion Assessment Method). Coma is defined as a RASS (Richmond Agitation-Sedation Scale ) assessment score of -4 or -5. |
| Family Satisfaction With Care in the Intensive Care Unit FS-ICU | One 10 minute survey will be given at patient's ICU discharge or extubation | (Aim3 )The Family Satisfaction with ICU Care (FS-ICU 24R) questionnaire overall satisfaction score is derived from questions 1 through 24 (26 items) and combines two subscale summary scores. The satisfaction with care summary score is derived from the questions numbered 1 through 14 (which consists of 16 questions because question 2 has parts a, b and c). The satisfaction with decision making summary score is derived from questions 15 through 24 (10 questions). All questions are coded as integers from 1 (worst) to 5 (best). Rescale the summary scores from 1 through 5 to 0 through 100 by subtracting 1 from the scores (so they can range from 0 to 4) and then multiplying each score by 25. |
| Electronic Visual Analogue Scale-validation Measure | Only measured at baseline, order of administration randomized before or after paper version | (Aim4) visual analogue touch screen scale via android tablet with REDCap link. Not able to calculate because the touch screen scale was unreliable. Patients often needed assistance with the touch screen cursor for this experimental measure. We determined that pencil and paper analogue scale was superior for this patient population. |
| Patient Satisfaction With Care | Measured at extubation or discharge from ICU which ever comes first | A 24-item survey with lower scores indicating greater satisfaction with care. |
| Family Member Anxiety | Baseline, patient extubation or discharge from ICU, 1-month, 3-month, 6-month post-discharge | (Aim 5) Hospital Anxiety and Depression Scale (HADS) Anxiety sub scale including 7 items each scored from 0-3 with total scores ranging from 0 - 21 with higher scores indicating higher levels of anxiety. |
| Mean Patient Reported Anxiety Score Using Visual Analogue Scale | Daily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICU | Aim 3 - Calculated mean of daily measure by patient mark (x) or point on the Visual Analogue Scale for anxiety, a 100 mm vertical line ranging from 0 (not anxious at all) to 10 (most anxious I've ever been). |
| Post-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R) | 1-month, 3-month, 6-month post-discharge | (Aim 5) Impact of Events Scale-revised. The IES-R is a 22-item self-report instrument with three subscales including intrusion (8 items), avoidance (8 items), and hyperarousal (6 items). The respondent is asked to report the degree of distress experienced for each item in the past 7 days. Each item is scored on a five-point Likert scale (0, not at all; 1, rarely; 2, occasionally; 3, fairly often; and 4, often) and total scores range from 0 to 88. Higher scores are representative of greater distress. |
| Family Communication Difficulty | baseline and extubation or discharge from the ICU | Family Communication Survey administered to participant families. Sum of 9-items with each item rating 0 (not at all) to 4 (extremely difficult), resulting in a total summed score from 0 - 36. Higher scores indicate greater difficulty. |
| Communication Task Error Rate | Measured during 30-60 minute usability testing visit which occurs at study completion. This outcome applies only to Aim 1 & 2 arms. | Aims 1 & 2 - count of the number of errors recorded by video screen capture for each of 8 communication tasks. Individual patients ranged from 0 to 9 errors, however this measure contains no upper range per task as it is a count of actual observed errors committed by patients. |
| Total Error Rate | Measured during 30-60 minute usability testing visit which occurs at study completion | Aims 1 & 2 - calculated mean of the total number of errors recorded by video screen capture divided by the number of communication tasks completed (8 maximum) Aim 1 extubated patients. Using group 1 and group 2 summary data, 11 patients completed 82 tasks (6 were abandoned, 5 of these by one patient). Removing abandonments, total number of errors = 25/ 82 tasks = 0.30 error rate. Aim 2 intubated patients. 11 patients completed 69 tasks (18 were abandoned; 1 task was refused). Removing abandonments, total number of errors = 60/ 69 tasks = 0.87error rate. |
| Patient Satisfaction With Communication Task Ease | Measured during 30-60 minute usability testing visit which occurs at study completion | Aims 1 & 2 - a single item from the After Scenario Questionnaire (ASQ) of patient's self rating of satisfaction with the ease of completing each of 8 communication tasks on the usability test. Question asked of patients was Overall, I am satisfied with the ease of completing this task. 1-strongly disagree 7-strongly agree. Higher scores indicated greater satisfaction with the ease of completing the task. |
| Observed Task Completion Time (in Seconds) | Measured during 30-60 minute usability testing visit which occurs at study completion | Aims 1 & 2 - This is the time, measured in seconds, on the screen capture recording beginning with the communication task command to patient completion of the communication task or message to patient completion of each of the 8 communication tasks on the usability test, calculated from the screen capture recordings |
| After-Scenario Questionnaire (ASQ) Score | Measured during 30-60 minute usability testing visit which occurs at study completion | Aims 1 & 2. The After-Scenario Questionnaire (ASQ) is a 3-item likert-type scale used to assess how difficult a user perceived a task in a usability test. Responses range from 1-strongly disagree to 7- strongly agree. Total score is the sum of the 3 items, possible scores range from 3 to 21. Higher scores indicated better outcomes. This was not measured for each task as that was too burdensome for intubated patients. We measured once as an overall rating at the end of the session- 3-item ASQ. |
| System Usability Scale (SUS) -Adapted | Measured during 30-60 minute usability testing visit which occurs at study completion | Aims 1 & 2, System Usability Scale is 13-item likert type scale with item ratings of 1 'strongly agree' to 7 'strongly disagree' to obtain the patient's rating of overall usability of the VidaTalk application, total scores range from 13 to 91 Note: This is different from the standard 10-item SUS that uses a 5-point scale, with scores ranging 0-100. |
| Number of Participants That Responded Yes to Having Communication Difficulty at Extubation or ICU Discharge | measured at Extubation /ICU Discharge | Measured as a single item : Question asked was - Presence of communication difficulty in the last few days? with answers being Yes or No |
| Family Member Depression | Baseline, patient extubation or discharge from ICU, 1-month, 3-month, 6-month post-discharge | (Aim 5). Hospital Anxiety and Depression Scale (HADS-D)- Depression Subscale including 7 items each scored from 0-3 with total scores ranging from 0 - 21 with higher scores indicating higher levels of depression symptoms. |
Countries
United States
Participant flow
Recruitment details
Patients were screened for eligibility by critical care research coordinators and referred to the study coordinator and research assistant for bedside eligibility screening and recruitment.
Participants by arm
| Arm | Count |
|---|---|
| Aim 1- VidaTalk Post-extubation Preliminary to clinical trial. Grp1+ Grp2 will each consist of five previously mechanically ventilated patients recruited from the ICUs at the OSUWMC.
Grp 1 will use an initial android prototype of VidaTalk tablet application assessed for functionality + usability on a series of scripted communication tasks.
Grp 2 will use an improved alpha prototype of VidaTalk tablet application version engineered from observations made during Grp 1 sessions.
Aim 1 - VidaTalk - post-extubation: Observation of task completion will be made while patients complete messages using the VidaTalk app:
Tired, Pain - rating, location, quality, Ask for doctor, Finger writing, Keyboard phrase. Patients will also complete 1-item difficulty rating + 3-item After-Scenario Questionnaire after each task.
Patients will rate the extent to which they would use the device if they were an ICU patient unable to speak.
Grp 1 only: will be asked their preferences for customizing the app. | 13 |
| Aim 2 - VidaTalk Intubated Usability testing preliminary to Clinical Trial. Mechanically Ventilated patients will provide feedback on acceptability, will perform test messages with minimal errors, and will rate VidaTalk an overall average score of 4.5 or higher (Likert-type scale; 1 to 7) on usability questions. Prior to implementing these procedures, the company will perform further iterative design assessments and engineer a Vidatalk tablet application prototype. This prototype will be used with a final group of ten (10) intubated patients receiving mechanical ventilation support to field-test the prototype for functionality (human-device interaction factors, feasibility, and usability) and acceptability.
Intervention is usability tasks with the VidaTalk app
Aim 2 - VidaTalk - intubated: Usability testing prior to clinical trial. The company will have performed further iterative design assessments and engineered a Vidatalk tablet application prototype for a field-test for functionality (human- | 23 |
| Aim 3 - VidaTalk Tablet App Test the clinical efficacy of VidaTalk with MV patients by examining qualitative & quantitative endpoints in a clinical setting. 35 intubated patients (oral endotracheal tube or tracheostomy) will be randomized to the intervention arm and will receive a protocolized instruction in the use of the VidaTalk application including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.
Intervention will be receipt of VidaTalk tablet application.
Aim 3 - VidaTalk tablet app: Patients in the intervention group will receive a protocolized instruction in the use of the VidaTalk application and mounting of the device including patient return demonstration. | 31 |
| Aim 3 - Attention-control 35 intubated patients (oral endotracheal tube or tracheostomy) will receive the standard of care, which may include primarily writing tools (paper and pen) and, occasionally, picture or alphabet communication charts.
Patients randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk application, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.
Interventions will be Aim 3 - attention-control with non-VidaTalk tablet.
Aim 3 - attention-control with non-VidaTalk tablet: Patents randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk app, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet. | 32 |
| Aim 5-VidaTalk Efficacy in Family Caregivers- VidaTalk Group Aim 5 will test the preliminary efficacy of VidaTalk compared to attention control (AC) on anxiety and depression symptoms in family caregivers during the ICU stay and post-discharge (1-mos; 3-mos; 6-mos) and PTSD-related symptoms post-discharge both qualitatively and quantitatively.
Aim 5.a.) Psychological outcomes (anxiety, depression, and PTSD-related symptoms) between the two groups will be compared at each time point and across time. Aim 5.b.) Family caregivers' perceived communication difficulty will be measured Aim 5.c.) Family caregivers' experience of communication while they were visiting the patient who received the VidaTalk app in the ICU and their emotional reactions to communication with a patient will be measured. | 18 |
| Aim 5 Family Caregiver- Attention Control Usual care condition for family communication with mechanically ventilated patients. Family caregivers receive tablet instruction sheet (no VidaTalk app). Family caregivers were asked to enter dates and times of visits into ICU bedside visitation log. | 16 |
| Total | 133 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 |
|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Death | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Overall Study | extubation or early discharge | 0 | 0 | 0 | 5 | 5 | 0 | 0 | 0 |
| Overall Study | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 6 |
| Overall Study | patient deterioration, fatigue | 2 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 2 | 0 | 1 | 1 | 0 | 8 | 1 |
Baseline characteristics
| Characteristic | Aim 2 - VidaTalk Intubated | Aim 3 - Attention-control | Aim 1- VidaTalk Post-extubation | Aim 5-VidaTalk Efficacy in Family Caregivers- VidaTalk Group | Aim 5 Family Caregiver- Attention Control | Total | Aim 3 - VidaTalk Tablet App |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 57.57 years STANDARD_DEVIATION 13.41 | 53.6 years STANDARD_DEVIATION 14.7 | 55.92 years STANDARD_DEVIATION 15.4 | 48.94 years STANDARD_DEVIATION 15.84 | 50.69 years STANDARD_DEVIATION 15.89 | 52.9 years STANDARD_DEVIATION 14.1 | 52.1 years STANDARD_DEVIATION 13.7 |
| Education High school graduate or less | 12 Participants | 13 Participants | 4 Participants | 5 Participants | 5 Participants | 58 Participants | 19 Participants |
| Education Some college | 7 Participants | 19 Participants | 7 Participants | 13 Participants | 11 Participants | 69 Participants | 12 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 23 Participants | 32 Participants | 13 Participants | 18 Participants | 16 Participants | 133 Participants | 31 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Family Caregiver Anxiety | — | — | — | 9.22 units on a scale STANDARD_DEVIATION 5.02 | 9.25 units on a scale STANDARD_DEVIATION 4.49 | 9.24 units on a scale STANDARD_DEVIATION 4.71 | — |
| Family Caregiver Depression | — | — | — | 5.89 units on a scale STANDARD_DEVIATION 3.85 | 5.25 units on a scale STANDARD_DEVIATION 4.17 | 5.59 units on a scale STANDARD_DEVIATION 3.96 | — |
| Family Communication Survey | — | — | — | 25.94 units on a scale STANDARD_DEVIATION 6.24 | 24.93 units on a scale STANDARD_DEVIATION 5.57 | 25.47 units on a scale STANDARD_DEVIATION 5.87 | — |
| Intubation Method oral intubation | 8 Participants | 16 Participants | — | — | — | 39 Participants | 15 Participants |
| Intubation Method tracheostomy | 11 Participants | 16 Participants | — | — | — | 43 Participants | 16 Participants |
| Patient Anxiety | — | 6.4 units on a scale STANDARD_DEVIATION 3.1 | — | — | — | 6.2 units on a scale STANDARD_DEVIATION 3 | 5.9 units on a scale STANDARD_DEVIATION 3 |
| Patient Communication Difficulty | 3.33 units on a scale STANDARD_DEVIATION 0.84 | 3.4 units on a scale STANDARD_DEVIATION 0.9 | 3.8 units on a scale STANDARD_DEVIATION 0.63 | — | — | 3.3 units on a scale STANDARD_DEVIATION 1.1 | 3.1 units on a scale STANDARD_DEVIATION 1.2 |
| Patient Frustration with Communication | 2.94 units on a scale STANDARD_DEVIATION 1.35 | 3.9 units on a scale STANDARD_DEVIATION 0.3 | 3.6 units on a scale STANDARD_DEVIATION 1.26 | — | — | 3.6 units on a scale STANDARD_DEVIATION 0.7 | 3.4 units on a scale STANDARD_DEVIATION 1 |
| Physical Restraint | — | 8 Participants | — | — | — | 13 Participants | 5 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 4 Participants | 0 Participants | 5 Participants | 3 Participants | 19 Participants | 5 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 20 Participants | 28 Participants | 12 Participants | 12 Participants | 13 Participants | 111 Participants | 26 Participants |
| severity of illness | 72.8 units on a scale STANDARD_DEVIATION 26.55 | 77.0 units on a scale STANDARD_DEVIATION 27.2 | 65.0 units on a scale STANDARD_DEVIATION 17.82 | — | — | 76.3 units on a scale STANDARD_DEVIATION 24.5 | 75.6 units on a scale STANDARD_DEVIATION 21.8 |
| Sex: Female, Male Female | 9 Participants | 12 Participants | 5 Participants | 15 Participants | 15 Participants | 69 Participants | 13 Participants |
| Sex: Female, Male Male | 14 Participants | 20 Participants | 8 Participants | 3 Participants | 1 Participants | 64 Participants | 18 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 13 | 0 / 23 | 2 / 31 | 0 / 32 | 0 / 0 | 0 / 18 | 0 / 16 | 0 / 7 | 0 / 7 |
| other Total, other adverse events | 0 / 13 | 0 / 23 | 0 / 31 | 0 / 32 | 0 / 0 | 0 / 18 | 0 / 16 | 0 / 7 | 0 / 7 |
| serious Total, serious adverse events | 0 / 13 | 0 / 23 | 0 / 31 | 0 / 32 | 0 / 0 | 0 / 18 | 0 / 16 | 0 / 7 | 0 / 7 |
Outcome results
Mean Daily Patient-reported Communication Difficulty Rating Using Single Item 0-4 Rating Scale
Aim 3 - Mean item score of daily by patient self report using a single item Likert-type scale from the Ease of Communication Scale (ECS) where scores range from 0 not hard at all to 4 extremely hard
Time frame: Daily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICU
Population: This outcome is only for the clinical trial. Applies only to Aim 3 arms.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Aim 3 - VidaTalk Tablet App | Mean Daily Patient-reported Communication Difficulty Rating Using Single Item 0-4 Rating Scale | 3.10 score on a scale | Standard Deviation 1.98 |
| Aim 3 - Attention-control | Mean Daily Patient-reported Communication Difficulty Rating Using Single Item 0-4 Rating Scale | 3.28 score on a scale | Standard Deviation 1.9 |
After-Scenario Questionnaire (ASQ) Score
Aims 1 & 2. The After-Scenario Questionnaire (ASQ) is a 3-item likert-type scale used to assess how difficult a user perceived a task in a usability test. Responses range from 1-strongly disagree to 7- strongly agree. Total score is the sum of the 3 items, possible scores range from 3 to 21. Higher scores indicated better outcomes. This was not measured for each task as that was too burdensome for intubated patients. We measured once as an overall rating at the end of the session- 3-item ASQ.
Time frame: Measured during 30-60 minute usability testing visit which occurs at study completion
Population: After Scenario Questionnaire is a 3-item patient rating of the usability of the VidaTalk communication application for each communication feature on ease, time, and support information
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Aim 1- VidaTalk Post-extubation | After-Scenario Questionnaire (ASQ) Score | Task 1 (Tired) | 18.2 score on a scale | Standard Deviation 3.92 |
| Aim 1- VidaTalk Post-extubation | After-Scenario Questionnaire (ASQ) Score | Task 2 (Pain) | 19.5 score on a scale | Standard Deviation 2.81 |
| Aim 1- VidaTalk Post-extubation | After-Scenario Questionnaire (ASQ) Score | Task 3 (Pain Rating) | 20.3 score on a scale | Standard Deviation 1.49 |
| Aim 1- VidaTalk Post-extubation | After-Scenario Questionnaire (ASQ) Score | Task 4 (Pain Location) | 20.1 score on a scale | Standard Deviation 2.02 |
| Aim 1- VidaTalk Post-extubation | After-Scenario Questionnaire (ASQ) Score | Task 5 (Pain Quality) | 20.7 score on a scale | Standard Deviation 0.949 |
| Aim 1- VidaTalk Post-extubation | After-Scenario Questionnaire (ASQ) Score | Task 6 (Doctor) | 18.1 score on a scale | Standard Deviation 4.28 |
| Aim 1- VidaTalk Post-extubation | After-Scenario Questionnaire (ASQ) Score | Task 7 (Word Draw) | 19.5 score on a scale | Standard Deviation 3.81 |
| Aim 1- VidaTalk Post-extubation | After-Scenario Questionnaire (ASQ) Score | Task 8 (Typing) | 18.1 score on a scale | Standard Deviation 5.45 |
| Aim 2 - VidaTalk Intubated | After-Scenario Questionnaire (ASQ) Score | Overall ASQ | 17.6 score on a scale | Standard Deviation 4.61 |
Communication Task Error Rate
Aims 1 & 2 - count of the number of errors recorded by video screen capture for each of 8 communication tasks. Individual patients ranged from 0 to 9 errors, however this measure contains no upper range per task as it is a count of actual observed errors committed by patients.
Time frame: Measured during 30-60 minute usability testing visit which occurs at study completion. This outcome applies only to Aim 1 & 2 arms.
Population: Aim 1 extubated patients. Using group 1 and group 2 summary data, 11 patients completed 82 tasks (6 were abandoned, 5 of these by one patient). Removing abandonments.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Aim 1- VidaTalk Post-extubation | Communication Task Error Rate | Task 1 (Tired) | .45 Errors |
| Aim 1- VidaTalk Post-extubation | Communication Task Error Rate | Task 5 (Pain Quality) | .40 Errors |
| Aim 1- VidaTalk Post-extubation | Communication Task Error Rate | Task 3 (Pain Rating) | .273 Errors |
| Aim 1- VidaTalk Post-extubation | Communication Task Error Rate | Task 6 (Doctor) | .20 Errors |
| Aim 1- VidaTalk Post-extubation | Communication Task Error Rate | Task 2 (Pain) | .09 Errors |
| Aim 1- VidaTalk Post-extubation | Communication Task Error Rate | Task 7 (Word Draw) | .22 Errors |
| Aim 1- VidaTalk Post-extubation | Communication Task Error Rate | Task 8 (Typing) | .50 Errors |
| Aim 1- VidaTalk Post-extubation | Communication Task Error Rate | Task 4 (Pain Location ) | .30 Errors |
| Aim 2 - VidaTalk Intubated | Communication Task Error Rate | Task 8 (Typing) | .50 Errors |
| Aim 2 - VidaTalk Intubated | Communication Task Error Rate | Task 1 (Tired) | 1.09 Errors |
| Aim 2 - VidaTalk Intubated | Communication Task Error Rate | Task 2 (Pain) | 1.0 Errors |
| Aim 2 - VidaTalk Intubated | Communication Task Error Rate | Task 3 (Pain Rating) | 1.0 Errors |
| Aim 2 - VidaTalk Intubated | Communication Task Error Rate | Task 4 (Pain Location ) | .36 Errors |
| Aim 2 - VidaTalk Intubated | Communication Task Error Rate | Task 5 (Pain Quality) | .63 Errors |
| Aim 2 - VidaTalk Intubated | Communication Task Error Rate | Task 6 (Doctor) | 1.18 Errors |
| Aim 2 - VidaTalk Intubated | Communication Task Error Rate | Task 7 (Word Draw) | .18 Errors |
Delirium/Coma -Free Days
Aim 3 -Delirium/coma-free days is defined as the number of days alive and free of delirium and coma during the 28-day study period. Delirium will be coded as present when a patient displays both features 1 and 2, and either 3 or 4 of the CAM-ICU (Confusion Assessment Method). Coma is defined as a RASS (Richmond Agitation-Sedation Scale ) assessment score of -4 or -5.
Time frame: Daily, from enrollment to 28 days post-enrollment
Population: Calculated as % days with delirium/total ICU days.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Aim 3 - VidaTalk Tablet App | Delirium/Coma -Free Days | 8.26 percent days with delirium/total ICU day |
| Aim 3 - Attention-control | Delirium/Coma -Free Days | 8.54 percent days with delirium/total ICU day |
Ease of Communication at Extubation /ICU Discharge
Ease of Communication Scale -10-item likert scale total score ranging from 0-40. Each item is 0-4 likert scale, total score is sum of all items with higher scores indicating greater communication difficulty.
Time frame: measured at Extubation /ICU Discharge
Population: Extubated ICU patients
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Aim 3 - VidaTalk Tablet App | Ease of Communication at Extubation /ICU Discharge | 23.19 score on a scale | Standard Deviation 11.31 |
| Aim 3 - Attention-control | Ease of Communication at Extubation /ICU Discharge | 27.23 score on a scale | Standard Deviation 10.46 |
Electronic Visual Analogue Scale-validation Measure
(Aim4) visual analogue touch screen scale via android tablet with REDCap link. Not able to calculate because the touch screen scale was unreliable. Patients often needed assistance with the touch screen cursor for this experimental measure. We determined that pencil and paper analogue scale was superior for this patient population.
Time frame: Only measured at baseline, order of administration randomized before or after paper version
Population: Not able to calculate because the touch screen scale was unreliable. Patients often needed assistance with the touch screen cursor for this experimental measure. We determined that pencil and paper analogue scale was superior for this patient population.
Family Communication Difficulty
Family Communication Survey administered to participant families. Sum of 9-items with each item rating 0 (not at all) to 4 (extremely difficult), resulting in a total summed score from 0 - 36. Higher scores indicate greater difficulty.
Time frame: baseline and extubation or discharge from the ICU
Population: Family Communication Survey baseline and extubation or discharge from the ICU
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Aim 5-VidaTalk Efficacy in Family Caregivers | Family Communication Difficulty | Baseline | 28.67 units on a scale | Standard Deviation 2.27 |
| Aim 5-VidaTalk Efficacy in Family Caregivers | Family Communication Difficulty | Extubation or Discharge from ICU | 33.67 units on a scale | Standard Deviation 1.6 |
| Aim-5 Control Group | Family Communication Difficulty | Baseline | 25.62 units on a scale | Standard Deviation 1.59 |
| Aim-5 Control Group | Family Communication Difficulty | Extubation or Discharge from ICU | 29.46 units on a scale | Standard Deviation 1.2 |
Family Member Anxiety
(Aim 5) Hospital Anxiety and Depression Scale (HADS) Anxiety sub scale including 7 items each scored from 0-3 with total scores ranging from 0 - 21 with higher scores indicating higher levels of anxiety.
Time frame: Baseline, patient extubation or discharge from ICU, 1-month, 3-month, 6-month post-discharge
Population: Baseline
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Aim 5-VidaTalk Efficacy in Family Caregivers | Family Member Anxiety | Patient Extubation or Discharge from ICU | 8.67 units on a scale | Standard Deviation 4.44 |
| Aim 5-VidaTalk Efficacy in Family Caregivers | Family Member Anxiety | 3-month | 6.83 units on a scale | Standard Deviation 4.92 |
| Aim 5-VidaTalk Efficacy in Family Caregivers | Family Member Anxiety | 1-month | 4.86 units on a scale | Standard Deviation 4.06 |
| Aim 5-VidaTalk Efficacy in Family Caregivers | Family Member Anxiety | 6-month | 6.80 units on a scale | Standard Deviation 5.63 |
| Aim 5-VidaTalk Efficacy in Family Caregivers | Family Member Anxiety | Baseline | 9.14 units on a scale | Standard Deviation 5.08 |
| Aim-5 Control Group | Family Member Anxiety | 6-month | 6.22 units on a scale | Standard Deviation 6.48 |
| Aim-5 Control Group | Family Member Anxiety | Baseline | 9.29 units on a scale | Standard Deviation 4.83 |
| Aim-5 Control Group | Family Member Anxiety | Patient Extubation or Discharge from ICU | 9.62 units on a scale | Standard Deviation 4.86 |
| Aim-5 Control Group | Family Member Anxiety | 1-month | 9.17 units on a scale | Standard Deviation 4.8 |
| Aim-5 Control Group | Family Member Anxiety | 3-month | 6.80 units on a scale | Standard Deviation 5.07 |
Family Member Depression
(Aim 5). Hospital Anxiety and Depression Scale (HADS-D)- Depression Subscale including 7 items each scored from 0-3 with total scores ranging from 0 - 21 with higher scores indicating higher levels of depression symptoms.
Time frame: Baseline, patient extubation or discharge from ICU, 1-month, 3-month, 6-month post-discharge
Population: Aim 5 Family member depression HADS-D subscale
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Aim 5-VidaTalk Efficacy in Family Caregivers | Family Member Depression | Patient Extubation or Discharge from ICU | 5.78 units on a scale | Standard Deviation 4.32 |
| Aim 5-VidaTalk Efficacy in Family Caregivers | Family Member Depression | 3-month | 7.03 units on a scale | Standard Deviation 3.98 |
| Aim 5-VidaTalk Efficacy in Family Caregivers | Family Member Depression | 1-month | 7.43 units on a scale | Standard Deviation 2.64 |
| Aim 5-VidaTalk Efficacy in Family Caregivers | Family Member Depression | 6-month | 6.33 units on a scale | Standard Deviation 4.27 |
| Aim 5-VidaTalk Efficacy in Family Caregivers | Family Member Depression | Baseline | 5.86 units on a scale | Standard Deviation 3.98 |
| Aim-5 Control Group | Family Member Depression | 6-month | 4.33 units on a scale | Standard Deviation 3.67 |
| Aim-5 Control Group | Family Member Depression | Baseline | 5.50 units on a scale | Standard Deviation 4.31 |
| Aim-5 Control Group | Family Member Depression | Patient Extubation or Discharge from ICU | 5.15 units on a scale | Standard Deviation 4.43 |
| Aim-5 Control Group | Family Member Depression | 1-month | 6.20 units on a scale | Standard Deviation 3.73 |
| Aim-5 Control Group | Family Member Depression | 3-month | 5.53 units on a scale | Standard Deviation 3.93 |
Family Satisfaction With Care in the Intensive Care Unit FS-ICU
(Aim3 )The Family Satisfaction with ICU Care (FS-ICU 24R) questionnaire overall satisfaction score is derived from questions 1 through 24 (26 items) and combines two subscale summary scores. The satisfaction with care summary score is derived from the questions numbered 1 through 14 (which consists of 16 questions because question 2 has parts a, b and c). The satisfaction with decision making summary score is derived from questions 15 through 24 (10 questions). All questions are coded as integers from 1 (worst) to 5 (best). Rescale the summary scores from 1 through 5 to 0 through 100 by subtracting 1 from the scores (so they can range from 0 to 4) and then multiplying each score by 25.
Time frame: One 10 minute survey will be given at patient's ICU discharge or extubation
Population: Total score on the Family Satisfaction in the Intensive Care Unit Survey (FS-ICU) completed by designated family caregiver-support person.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Aim 3 - VidaTalk Tablet App | Family Satisfaction With Care in the Intensive Care Unit FS-ICU | 81.8 score on a scale | Standard Deviation 13.8 |
| Aim 3 - Attention-control | Family Satisfaction With Care in the Intensive Care Unit FS-ICU | 92.4 score on a scale | Standard Deviation 7.2 |
Mean Daily Sedation Exposure
Used in Aim 3 only. Calculation of benzodiazepine and morphine equivalents (for opiates) using hospital conversion charts (pharmacy conversion chart). All benzo IV doses were converted to Lorazepam IV doses. All opioid IV doses were converted to morphine IV doses. All benzo oral doses were converted to Lorazepam oral doses. All opioid oral doses were converted to morphine oral doses. Oral doses were converted to IV equivalents. Summed doses of Lorazepam IV and morphine IV were calculated for each study day for each patient. Doses were converted to milligrams per kilogram based on the patient's body weight. Higher numbers indicate greater sedation and/or opiate exposure.
Time frame: Daily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICU daily in ICU
Population: P-values were derived from mixed-effects regression using rank-based sedation exposure
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Aim 3 - VidaTalk Tablet App | Mean Daily Sedation Exposure | Benzo (mg/kg) | .01 mg/kg | Standard Deviation 0.05 |
| Aim 3 - VidaTalk Tablet App | Mean Daily Sedation Exposure | Morphine (mg/kg) | .84 mg/kg | Standard Deviation 2.1 |
| Aim 3 - Attention-control | Mean Daily Sedation Exposure | Benzo (mg/kg) | .008 mg/kg | Standard Deviation 0.02 |
| Aim 3 - Attention-control | Mean Daily Sedation Exposure | Morphine (mg/kg) | .24 mg/kg | Standard Deviation 0.5 |
Mean Patient Frustration With Communication
Aim 3 - This will be the calculated mean of the daily Communication Frustration scale - a single item scale reported by the patient, ranging from 0 not frustrating to 4 extremely frustrating
Time frame: Daily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICU
Population: This information is for Aim 3 only.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Aim 3 - VidaTalk Tablet App | Mean Patient Frustration With Communication | 3.14 units on a scale | Standard Deviation 1.89 |
| Aim 3 - Attention-control | Mean Patient Frustration With Communication | 3.53 units on a scale | Standard Deviation 0.17 |
Mean Patient Reported Anxiety Score Using Visual Analogue Scale
Aim 3 - Calculated mean of daily measure by patient mark (x) or point on the Visual Analogue Scale for anxiety, a 100 mm vertical line ranging from 0 (not anxious at all) to 10 (most anxious I've ever been).
Time frame: Daily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICU
Population: This Secondary Outcome is for participants in Aim 3 only.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Aim 3 - VidaTalk Tablet App | Mean Patient Reported Anxiety Score Using Visual Analogue Scale | 5.55 score on a scale | Standard Deviation 6.54 |
| Aim 3 - Attention-control | Mean Patient Reported Anxiety Score Using Visual Analogue Scale | 6.02 score on a scale | Standard Deviation 6.07 |
Number of Participants That Responded Yes to Having Communication Difficulty at Extubation or ICU Discharge
Measured as a single item : Question asked was - Presence of communication difficulty in the last few days? with answers being Yes or No
Time frame: measured at Extubation /ICU Discharge
Population: Extubated ICU patients
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Aim 1- VidaTalk Post-extubation | Number of Participants That Responded Yes to Having Communication Difficulty at Extubation or ICU Discharge | 0 Participants |
| Aim 2 - VidaTalk Intubated | Number of Participants That Responded Yes to Having Communication Difficulty at Extubation or ICU Discharge | 0 Participants |
| Aim 3 - VidaTalk Tablet App | Number of Participants That Responded Yes to Having Communication Difficulty at Extubation or ICU Discharge | 14 Participants |
| Aim 3 - Attention-control | Number of Participants That Responded Yes to Having Communication Difficulty at Extubation or ICU Discharge | 23 Participants |
| Aim 5-VidaTalk Efficacy in Family Caregivers | Number of Participants That Responded Yes to Having Communication Difficulty at Extubation or ICU Discharge | 0 Participants |
Observed Task Completion Time (in Seconds)
Aims 1 & 2 - This is the time, measured in seconds, on the screen capture recording beginning with the communication task command to patient completion of the communication task or message to patient completion of each of the 8 communication tasks on the usability test, calculated from the screen capture recordings
Time frame: Measured during 30-60 minute usability testing visit which occurs at study completion
Population: This is the time, measured in seconds, on the screen capture recording beginning with the communication task command to patient completion of the communication task or message to patient completion of each of the 8 communication tasks on the usability test, calculated from the screen capture recordings
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Aim 1- VidaTalk Post-extubation | Observed Task Completion Time (in Seconds) | Task 1 (Tired) | 64.27 seconds | Standard Deviation 69.02 |
| Aim 1- VidaTalk Post-extubation | Observed Task Completion Time (in Seconds) | Task 2 (Pain) | 16.73 seconds | Standard Deviation 13.06 |
| Aim 1- VidaTalk Post-extubation | Observed Task Completion Time (in Seconds) | Task 3 (Pain Rating) | 26.6 seconds | Standard Deviation 26.71 |
| Aim 1- VidaTalk Post-extubation | Observed Task Completion Time (in Seconds) | Task 4 (Pain Location) | 25.3 seconds | Standard Deviation 34.19 |
| Aim 1- VidaTalk Post-extubation | Observed Task Completion Time (in Seconds) | Task 5 (Pain Quality) | 44.0 seconds | Standard Deviation 75.83 |
| Aim 1- VidaTalk Post-extubation | Observed Task Completion Time (in Seconds) | Task 6 (Doctor) | 53.9 seconds | Standard Deviation 35.86 |
| Aim 1- VidaTalk Post-extubation | Observed Task Completion Time (in Seconds) | Task 7 (Word Draw) | 22.22 seconds | Standard Deviation 25.06 |
| Aim 1- VidaTalk Post-extubation | Observed Task Completion Time (in Seconds) | Task 8 (Typing) | 57.7 seconds | Standard Deviation 61.18 |
| Aim 2 - VidaTalk Intubated | Observed Task Completion Time (in Seconds) | Task 8 (Typing) | 73.3 seconds | Standard Deviation 53.4 |
| Aim 2 - VidaTalk Intubated | Observed Task Completion Time (in Seconds) | Task 1 (Tired) | 117.45 seconds | Standard Deviation 107.29 |
| Aim 2 - VidaTalk Intubated | Observed Task Completion Time (in Seconds) | Task 5 (Pain Quality) | 52.73 seconds | Standard Deviation 49.26 |
| Aim 2 - VidaTalk Intubated | Observed Task Completion Time (in Seconds) | Task 2 (Pain) | 80.0 seconds | Standard Deviation 143.62 |
| Aim 2 - VidaTalk Intubated | Observed Task Completion Time (in Seconds) | Task 7 (Word Draw) | 37.55 seconds | Standard Deviation 25.28 |
| Aim 2 - VidaTalk Intubated | Observed Task Completion Time (in Seconds) | Task 3 (Pain Rating) | 74.0 seconds | Standard Deviation 64.35 |
| Aim 2 - VidaTalk Intubated | Observed Task Completion Time (in Seconds) | Task 6 (Doctor) | 100.0 seconds | Standard Deviation 75.51 |
| Aim 2 - VidaTalk Intubated | Observed Task Completion Time (in Seconds) | Task 4 (Pain Location) | 34.82 seconds | Standard Deviation 34.19 |
Patient Satisfaction With Care
A 24-item survey with lower scores indicating greater satisfaction with care.
Time frame: Measured at extubation or discharge from ICU which ever comes first
Population: Patient Satisfaction with Care at extubation /ICU discharge single item likert type scale 1 (very dissatisfied) to 5 (very satisfied)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Aim 3 - VidaTalk Tablet App | Patient Satisfaction With Care | 4.45 units on a scale | Standard Deviation 1.01 |
| Aim 3 - Attention-control | Patient Satisfaction With Care | 4.56 units on a scale | Standard Deviation 0.92 |
Patient Satisfaction With Communication Task Ease
Aims 1 & 2 - a single item from the After Scenario Questionnaire (ASQ) of patient's self rating of satisfaction with the ease of completing each of 8 communication tasks on the usability test. Question asked of patients was Overall, I am satisfied with the ease of completing this task. 1-strongly disagree 7-strongly agree. Higher scores indicated greater satisfaction with the ease of completing the task.
Time frame: Measured during 30-60 minute usability testing visit which occurs at study completion
Population: Aim 1 Extubated patients - mean Task Ease Rating Aim 2 Intubated patients - mean Task Ease Rating
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Aim 1- VidaTalk Post-extubation | Patient Satisfaction With Communication Task Ease | Task 1 (Tired) | 5.7 score on a scale | Standard Deviation 1.85 |
| Aim 1- VidaTalk Post-extubation | Patient Satisfaction With Communication Task Ease | Task 2 (Pain) | 6.7 score on a scale | Standard Deviation 0.647 |
| Aim 1- VidaTalk Post-extubation | Patient Satisfaction With Communication Task Ease | Task 3 (Pain Rating) | 6.7 score on a scale | Standard Deviation 0.675 |
| Aim 1- VidaTalk Post-extubation | Patient Satisfaction With Communication Task Ease | Task 4 (Pain Location) | 6.7 score on a scale | Standard Deviation 0.675 |
| Aim 1- VidaTalk Post-extubation | Patient Satisfaction With Communication Task Ease | Task 5 (Pain Quality) | 6.9 score on a scale | Standard Deviation 0.316 |
| Aim 1- VidaTalk Post-extubation | Patient Satisfaction With Communication Task Ease | Task 6 (Doctor) | 5.8 score on a scale | Standard Deviation 1.68 |
| Aim 1- VidaTalk Post-extubation | Patient Satisfaction With Communication Task Ease | Task 7 (Draw Word) | 6.9 score on a scale | Standard Deviation 0.316 |
| Aim 1- VidaTalk Post-extubation | Patient Satisfaction With Communication Task Ease | Task 8 (Typing) | 5.9 score on a scale | Standard Deviation 2.08 |
| Aim 2 - VidaTalk Intubated | Patient Satisfaction With Communication Task Ease | Overall Ease | 5.82 score on a scale | Standard Deviation 1.6 |
Percentage of Patients Scoring in the Calm Range During Study Days on Richmond Agitation Sedation Score
The Richmond Agitation Sedation Scale, a 10-level observational rating of agitation-sedation motor activity ranging from +4 'combative' to -5 unresponsive, with 0 as calm. Since this is a categorical measure, we compared proportion of patients with RASS in -1 to +1 (calm) range during study days.
Time frame: Daily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICU
Population: Since this is a categorical measure, we compared percentage of patients with RASS in -1 to +1 (calm) range during study days.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Aim 3 - VidaTalk Tablet App | Percentage of Patients Scoring in the Calm Range During Study Days on Richmond Agitation Sedation Score | 81.48 percentage of participants in calm range |
| Aim 3 - Attention-control | Percentage of Patients Scoring in the Calm Range During Study Days on Richmond Agitation Sedation Score | 77.78 percentage of participants in calm range |
Post-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R)
(Aim 5) Impact of Events Scale-revised. The IES-R is a 22-item self-report instrument with three subscales including intrusion (8 items), avoidance (8 items), and hyperarousal (6 items). The respondent is asked to report the degree of distress experienced for each item in the past 7 days. Each item is scored on a five-point Likert scale (0, not at all; 1, rarely; 2, occasionally; 3, fairly often; and 4, often) and total scores range from 0 to 88. Higher scores are representative of greater distress.
Time frame: 1-month, 3-month, 6-month post-discharge
Population: Impact of events scale median/IQR
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Aim 5-VidaTalk Efficacy in Family Caregivers | Post-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R) | 1-month | 21.5 units on a scale |
| Aim 5-VidaTalk Efficacy in Family Caregivers | Post-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R) | 3-months | 21 units on a scale |
| Aim 5-VidaTalk Efficacy in Family Caregivers | Post-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R) | 6-months | 23 units on a scale |
| Aim-5 Control Group | Post-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R) | 1-month | 30.5 units on a scale |
| Aim-5 Control Group | Post-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R) | 3-months | 27.5 units on a scale |
| Aim-5 Control Group | Post-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R) | 6-months | 26 units on a scale |
System Usability Scale (SUS) -Adapted
Aims 1 & 2, System Usability Scale is 13-item likert type scale with item ratings of 1 'strongly agree' to 7 'strongly disagree' to obtain the patient's rating of overall usability of the VidaTalk application, total scores range from 13 to 91 Note: This is different from the standard 10-item SUS that uses a 5-point scale, with scores ranging 0-100.
Time frame: Measured during 30-60 minute usability testing visit which occurs at study completion
Population: Note: This is different from the standard 10-item SUS that uses a 5-point scale, with scores ranging 0-100.~Aim 3 and 5 were not addressed with this question.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Aim 1- VidaTalk Post-extubation | System Usability Scale (SUS) -Adapted | 82.5 units on a scale | Standard Deviation 5.91 |
| Aim 2 - VidaTalk Intubated | System Usability Scale (SUS) -Adapted | 68.5 units on a scale | Standard Deviation 12.37 |
Total Error Rate
Aims 1 & 2 - calculated mean of the total number of errors recorded by video screen capture divided by the number of communication tasks completed (8 maximum) Aim 1 extubated patients. Using group 1 and group 2 summary data, 11 patients completed 82 tasks (6 were abandoned, 5 of these by one patient). Removing abandonments, total number of errors = 25/ 82 tasks = 0.30 error rate. Aim 2 intubated patients. 11 patients completed 69 tasks (18 were abandoned; 1 task was refused). Removing abandonments, total number of errors = 60/ 69 tasks = 0.87error rate.
Time frame: Measured during 30-60 minute usability testing visit which occurs at study completion
Population: Aim 1 extubated patients. Using group 1 and group 2 summary data, 11 patients completed 82 tasks (6 were abandoned, 5 of these by one patient).~Aim 2 intubated patients. 11 patients completed 69 tasks (18 were abandoned; 1 task was refused).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Aim 1- VidaTalk Post-extubation | Total Error Rate | 0.30 error rate |
| Aim 2 - VidaTalk Intubated | Total Error Rate | 0.87 error rate |